Oncology | Phase I Developments | ISRAEL

Compugen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Compugen Expands Patent Portfolio for TIGIT Inhibitor COM902 with New US Composition of Matter Patent

Lead Product(s): COM902,COM701

Therapeutic Area: Oncology Product Name: COM902

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 28, 2020

Details:

The U.S. Patent titled “Anti-TIGIT Antibodies, Anti-PVRIG Antibodies and Combinations Thereof,” relates to the composition of matter of COM902, alone or in combination with a second antibody targeting an immune checkpoint, including PD-1 and PVRIG (specifically COM701).

Kitov Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Kitov Pharma Receives Notice of Intention to Grant a European Patent Covering CM24, its anti-CEACAM1 Antibody

Lead Product(s): CM-24,Nivolumab

Therapeutic Area: Oncology Product Name: CM-24

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 08, 2020

Details:

Kitov is currently advancing preparations to initiate a Phase 1/2 clinical trial of CM24 in combination with Opdivo in patients with non-small cell lung cancer, and in combination with nivolumab in addition to standard of care chemotherapy in patients with pancreatic cancer.

Compugen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Compugen Doses First Patient in COM701 Phase 1 Monotherapy Expansion Cohort

Lead Product(s): COM701

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 27, 2020

Details:

First patient has been dosed in the monotherapy expansion cohort of its ongoing Phase 1 clinical trial of COM701, a first-in-class anti-PVRIG antibody.

Kitov Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Kitov to Present Phase 1 Data on CM-24 in Patients with Advanced Cancer at ASCO 2020 Virtual Scientific Program

Lead Product(s): CM-24

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 14, 2020

Details:

Positive results of a previously reported Phase 1 trial of CM-24, a monoclonal antibody targeting CEACAM1, in patients with advanced cancer will be presented in a poster presentation at the American Society of Clinical Oncology (ASCO) 2020.

Compugen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Compugen Expands Intellectual Property Portfolio for COM701 With New European Composition of Matter Patent

Lead Product(s): COM701

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 22, 2020

Details:

EPO Patent covers the composition of matter for COM701 and backup antibodies including any anti-PVRIG antibody having the binding fragments of COM701 or backup antibodies for the treatment of cancer.

Kitov Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Kitov Pharma Ltd. Announces Cash Proceeds of $6.5 Million from Exercise of Warrants

Lead Product(s): CM-24

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: H.C. Wainwright & Co

Deal Size: $6.5 million Upfront Cash: Undisclosed

Deal Type: Public Offering April 20, 2020

Details:

Kitov intends to use the net proceeds from this offering to fund the development of its oncology therapeutic candidates, and for general working capital purposes.

Compugen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Compugen Announces Publication of BAY 1905254 Preclinical Data in Cancer Immunology Research

Lead Product(s): BAY 1905254

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 20, 2020

Details:

BAY 1905254, is currently being evaluated by Bayer in a Phase 1 study in advanced solid tumors. Preclinical studies showed BAY 1905254 in vitro T cell activation and in vivo anti-tumor activity.

Compugen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the 2020 AACR Virtual Annual Meeting

Lead Product(s): COM701

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 14, 2020

Details:

The presentation highlighted positive results of the dose escalation arms of COM701 monotherapy and in combination with nivolumab.

Compugen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Compugen Announces First Patient Dosed in COM902 Phase 1 Trial for Patients With Advanced Malignancies

Lead Product(s): COM902

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 06, 2020

Details:

COM902 and COM701 will allow the Company to clinically evaluate the dual blockade of PVRIG and TIGIT inhibitory pathways in the DNAM axis .

Compugen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Compugen Announces Updated Clinical Data from Ongoing COM701 Phase 1 Study

Lead Product(s): COM701

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 09, 2020

Details:

COM701 demonstrates preliminary antitumor activity with confirmed partial responses as monotherapy in a patient with primary peritoneal cancer and in combination with Opdivo in MSS-CRC.

Find

Find Oncology Drugs in Phase I Clinical Development in ISRAEL

Israel

Product Type

Companies

Compugen

Compugen Expands Patent Portfolio for TIGIT Inhibitor COM902 with New US Composition of Matter Patent

Kitov Pharma

Kitov Pharma Receives Notice of Intention to Grant a European Patent Covering CM24, its anti-CEACAM1 Antibody

Compugen

Compugen Doses First Patient in COM701 Phase 1 Monotherapy Expansion Cohort

Kitov Pharma

Kitov to Present Phase 1 Data on CM-24 in Patients with Advanced Cancer at ASCO 2020 Virtual Scientific Program

Compugen

Compugen Expands Intellectual Property Portfolio for COM701 With New European Composition of Matter Patent

Kitov Pharma

Kitov Pharma Ltd. Announces Cash Proceeds of $6.5 Million from Exercise of Warrants

Compugen

Compugen Announces Publication of BAY 1905254 Preclinical Data in Cancer Immunology Research

Compugen

Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the 2020 AACR Virtual Annual Meeting

Compugen

Compugen Announces First Patient Dosed in COM902 Phase 1 Trial for Patients With Advanced Malignancies

Compugen

Compugen Announces Updated Clinical Data from Ongoing COM701 Phase 1 Study